Shuzhidao

Shuzhidao operates as a platform-type surgical robotics company headquartered in Shanghai, focusing on developing intelligent surgical systems across medical aesthetics, oncology, and vascular intervention domains. The company has achieved NMPA approval for both its dental implant robot and hair transplant robot, positioning itself among China’s emerging multi-specialty surgical robot developers.

Company Overview

Founded in 2021, Shuzhidao has rapidly established itself in China’s surgical robotics sector through a distinctive “robot platform + intelligent consumables” business model. Rather than focusing on a single surgical specialty, the company strategically targets three major therapeutic areas with over ten products in various development stages. CEO Yang Situ leads the company’s efforts to transform traditional manual surgical procedures into standardized, automated operations.

The company secured Series A financing led by Jifeng Capital in April 2022, followed by Series A+ funding led by Mifang Health Fund in 2023. These investments have supported the development of its proprietary six-axis robotic arm technology and visual servo systems that form the foundation of its product portfolio.

Core Products

Dental Implant Surgical Robot

Shuzhidao’s oral implant robot received NMPA approval in April 2024, marking a significant milestone for the company. The system integrates a self-developed six-axis robotic arm designed to mimic natural hand movements within the confined oral cavity. Key features include force feedback sensing, real-time patient tracking through visual servo technology, and image-guided navigation that enables immediate post-extraction implant placement.

Hair Transplant Robot

The company’s hair transplant robot represents China’s first domestically developed system to enter NMPA registration clinical trials and subsequently receive approval. Utilizing high-definition stereoscopic imaging combined with visual servo technology, the system achieves positioning accuracy of 0.1mm. The robot employs micro-needle technology with tips smaller than 1mm, reducing tissue trauma compared to international competitors requiring larger instruments.

Vascular Interventional Robot (In Development)

As part of its three-pillar strategy, Shuzhidao is developing vascular interventional robotic systems, though these products remain in the research phase.

Technology & Innovation

Shuzhidao’s technical architecture centers on several proprietary technologies. The self-developed six-axis robotic arm provides the mechanical foundation across all products, featuring lightweight construction optimized for response speed and operational consistency. The force feedback system enables operators to perceive subtle resistance changes during procedures, enhancing safety and precision.

The visual servo system employs advanced sensors and tracking algorithms to monitor patient micro-movements in real-time, automatically compensating for positional changes during surgery. This capability proves particularly valuable in dental procedures where patient head movement can affect implant placement accuracy.

The company maintains full intellectual property rights over its robotic arm, vision system, and intelligent algorithms, enabling rapid product iteration and customization for specific clinical requirements.

Market Presence

Shuzhidao targets the intersection of surgical robotics and medical aesthetics, capitalizing on China’s rapidly growing markets for dental implants and hair restoration. The hair transplant market in particular shows strong domestic demand, with China achieving a 0.21% procedure penetration rate—significantly higher than other Asian markets.

The company’s commercial deployment has begun, with the hair transplant robot completing procedures at institutions including Zhejiang University School of Medicine affiliated Hangzhou First People’s Hospital and Shao Yifu International Medical Center. The dental implant robot is positioned to serve the growing demand for precision-guided oral surgery.

Key Milestones

• 2021: Company founded in Shanghai
• 2022: Completed Series A financing led by Jifeng Capital
• 2023: Series A+ financing led by Mifang Health Fund; hair transplant robot entered clinical trials
• 2024: Dental implant surgical robot received NMPA approval (April); hair transplant robot received NMPA approval
• 2025: Hair transplant robot commercial cases completed

Frequently Asked Questions

What products does Shuzhidao offer?

Shuzhidao has two NMPA-approved products: a dental implant surgical robot and a hair transplant robot. Both systems use the company’s proprietary six-axis robotic arm and visual servo technology. Additional products targeting oncology and vascular intervention are in development.

Is Shuzhidao publicly traded?

No, Shuzhidao remains privately held. The company has completed Series A and Series A+ financing rounds with investors including Jifeng Capital and Mifang Health Fund.

What makes Shuzhidao’s hair transplant robot different from competitors?

The Shuzhidao hair transplant robot employs a non-invasive tensioning approach and micro-needle technology with tips smaller than 1mm, contrasting with international systems that require larger diameter instruments. The system achieves 0.1mm positioning accuracy and maintains hair follicle survival rates of 95%, while reducing procedure time and physician fatigue.